Tyme Technologies, Inc. has been working on cancer drug development under the radar, but positive early data on its sole clinical-stage drug – a cancer therapy called SM-88 – has encouraged management to move ahead more aggressively into larger mid-stage clinical testing.
The New York City-based biotech presented positive interim data from a Phase II clinical trial in prostate cancer patients at...